Rosetta Genomics Reports Second Quarter 2008 Financi...(cated in Bensalem Pennsylvania. The...)

Bensalem, Pennsylvania. The acquisition is expected to allow Rosetta

Genomics to expedite development and validation of its microRNA-based

diagnostic tests both in the U.S. and worldwide. In addition, ownership

of the CLIA-certified lab will allow Rosetta Genomics to control the

commercialization of its diagnostics, including marketing, sales, and

reimbursement strategy.

The Company expects the first tests will be launched through the lab during Q4, 2008.

Collaborations and Licensing

- Initiated a clinical validation study with The University of

Texas M. D. Anderson Cancer Center. The study will focus on Rosetta

Genomics' microRNA-based test that identifies the primary site of

cancer of unknown primary (CUP) origin. The study will include one

hundred patients who are diagnosed with CUP at M. D. Anderson, and who

meet the eligibility criteria.

- Initiated a research collaboration with The University of

Texas M. D. Anderson Cancer Center and the Kleberg Center for Molecular

Markers to develop a microRNA-based diagnostic test to predict risk of

disease recurrence in lung cancer patients who have undergone curative

resection.

- Signed a collaboration agreement with the Rabin Medical

Center in Israel to develop microRNA-based diagnostics in the fields of

oncology, gynecology, and obstetrics. The collaboration will leverage

microRNAs' significant potential as highly sensitive and specific

biomarkers, to develop a wide range of diagnostic and prognostic tests.

This is the company's first collaboration to include a focus on

diagnostics for women's health indications.

Publications

- Published results of a study conducted by Rosetta Genomics'

scientists and collaborators that describes the use of microRNAs in

accurately differentiat
'/>"/>